Physician profile
Sandra Caskie
NPI 1568431815
$423.42
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308 · 2020: $116.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $115.13 | 2019-2020 | |
| Daiichi Sankyo INC. | $66.77 | 2019 | |
| Exeltis, USA INC. | $61.83 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.81 | 2019 | |
| Duchesnay USA Incorporated | $22.67 | 2019 | |
| Therapeuticsmd, INC. | $18.92 | 2020 | |
| Merck Sharp & Dohme LLC | $17.71 | 2019 | |
| Amag Pharmaceuticals, INC. | $16.19 | 2019 | |
| Mission Pharmacal Company | $15.00 | 2019 | |
| Hologic Sales and Service, LLC | $14.74 | 2020 | |
| Millicent US INC | $13.51 | 2019 | |
| Vertical Pharmaceuticals, LLC | $12.72 | 2019 | |
| Allergan, INC. | $11.42 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Caskie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.